In fact, combinations of both types of inhibitors (anti-PD-1/PD-L1 combined with anti-CTLA-4 agents) are currently undergoing clinical trials for BlCa patients [31,32], following the success observed in melanoma patients [33]. The gene discussed is CD274; the disease is bladder transitional cell carcinoma.